Medical technology company Haemonetics has announced the limited market release of the VASCADE MVP XL, a new addition to its portfolio of vascular closure devices.
The mid-bore venous closure device represents an expansion of the Haemonetics’ VASCADE product line featuring unique collapsible disc technology and a resorbable collagen patch that facilitates rapid haemostasis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The VASCADE MVP XL is tailored for larger procedural sheaths used in complex interventions, accommodating sheaths up to 15F in outer diameter.
This device distinguishes itself by incorporating 58% more collagen and a larger disc compared with its predecessor, the VASCADE MVP system.
The enhancement is specifically aimed at providing a robust closure for procedures that require 10–12F sheaths, such as cryoablation and left atrial appendage closure, which are common in the treatment of atrial fibrillation patients.
Haemonetics Global Hospital president Stew Strong said: “With VASCADE MVP XL, Haemonetics continues to expand its presence and broaden its reach in the $2.7bn total addressable market for vascular closure solutions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The introduction of VASCADE MVP XL underscores our commitment to innovation and improving patient care, as we enhance our range of vascular closure solutions to address increasing demand for catheter-based ablation technologies. We are enthusiastic about the initial launch of VASCADE MVP XL and anticipate a full market release later this year.”
Earlier this year, the VASCADE MVP XL system obtained US Food and Drug Administration (FDA) pre-market approval.
The commencement of the limited market release was marked by the first successful procedure using the VASCADE MVP XL, performed at the University of Alabama at Birmingham.
It was performed by University of Alabama Heart & Vascular Center co-director and Electrophysiology section chief Dr Tom McElderry.
In March 2024, Haemonetics agreed to acquire Attune Medical, which manufactures the ensoETM proactive oesophageal cooling device, for an upfront payment of $160m.
